Holen Sie sich die Stockscreener-App
6.84
1.18%
0.08
Handel nachbörslich:
6.84
Schlusskurs vom Vortag:
$6.76
Offen:
$6.69
24-Stunden-Volumen:
1.19M
Relative Volume:
1.04
Marktkapitalisierung:
$731.77M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-167.48M
KGV:
-3.5077
EPS:
-1.95
Netto-Cashflow:
$-197.47M
1W Leistung:
+1.18%
1M Leistung:
-21.11%
6M Leistung:
-54.64%
1J Leistung:
-53.94%
1-Tages-Spanne:
$6.63
$6.88
1-Wochen-Bereich:
$6.60
$7.42
52-Wochen-Spanne:
$6.41
$18.07
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Firmenname
Day One Biopharmaceuticals Inc
Sektor
Branche
Telefon
650 484-0899
Adresse
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
Vergleichen Sie DAWN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
6.84 | 731.77M | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-09 | Bestätigt | Needham | Buy |
| 2024-08-01 | Hochstufung | BofA Securities | Underperform → Buy |
| 2024-04-24 | Bestätigt | Needham | Buy |
| 2023-04-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-02-08 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-03 | Eingeleitet | Oppenheimer | Perform |
| 2022-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Buy |
| 2022-12-01 | Eingeleitet | BofA Securities | Buy |
Alle ansehen
Day One Biopharmaceuticals Inc Aktie (DAWN) Neueste Nachrichten
BofA Adjusts Price Target on Day One Biopharmaceuticals to $21 From $24, Keeps Buy Rating - MarketScreener
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Corebridge Financial Inc. - Defense World
Vanguard Group Inc. Lowers Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity - Seeking Alpha
Day One Biopharmaceuticals, Inc. (DAWN): Among Stocks Under $10 that Will Triple - MSN
KLP Kapitalforvaltning AS Invests $150,000 in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
10 Stocks Under $10 that Will Triple - Insider Monkey
HC Wainwright Analysts Decrease Earnings Estimates for DAWN - Defense World
HC Wainwright Reaffirms Buy Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - Defense World
H.C. Wainwright maintains Buy on Day One Biopharmaceuticals By Investing.com - Investing.com Canada
Teacher Retirement System of Texas Buys 3,086 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of “Buy” by Analysts - The AM Reporter
(DAWN) Investment Report - news.stocktradersdaily.com
Swiss National Bank Grows Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Charles Schwab Investment Management Inc. Grows Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Position Boosted by Bank of New York Mellon Corp - Defense World
Buy Rating for Day One Biopharmaceuticals: Strong Financial Position and Strategic Growth Potential - TipRanks
Does Wolfspeed Inc (NYSE: WOLF) Still Look Hot This Week? - stocksregister.com
(DAWN) Proactive Strategies - Stock Traders Daily
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Rhumbline Advisers Has $957,000 Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 5.5% on Analyst Downgrade - Defense World
JPMorgan Chase & Co. Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $34.00 - Defense World
Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory - Insider Monkey
Glioma Treatment Market Size Report 2034 | AnHeart Therapeutics - openPR.com
HC Wainwright Issues Positive Estimate for DAWN Earnings - MarketBeat
What is Wedbush's Forecast for DAWN Q1 Earnings? - MarketBeat
Research Analysts Offer Predictions for DAWN Q1 Earnings - Defense World
Needham & Company LLC Reaffirms Buy Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat
What is Wedbush’s Forecast for DAWN Q1 Earnings? - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Quarterly Earnings Results, Misses Estimates By $0.34 EPS - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Earnings Results, Misses Expectations By $0.34 EPS - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year Low After Earnings Miss - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $36.00 Price Target at HC Wainwright - MarketBeat
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates - MSN
Wedbush Reiterates “Outperform” Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Earns “Buy” Rating from Needham & Company LLC - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week Low Following Weak Earnings - Defense World
Day One Biopharma’s Earnings Call Highlights Growth and Challenges - TipRanks
Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Profit Outlook - Simply Wall St
Promising Growth Potential for Day One Biopharmaceuticals Driven by Ojemda and FIREFLY-2 Trial - TipRanks
Day One Biopharmaceuticals' (DAWN) Outperform Rating Reiterated at Wedbush - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Day One Biopharmaceuticals Q4 2024 results show growth - Investing.com Australia
Earnings call transcript: Day One Biopharmaceuticals Q4 2024 results show growth By Investing.com - Investing.com South Africa
Day One Biopharmaceuticals Reports Strong 2024 Results - TipRanks
Adam Dubow Sells 4,646 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock - MarketBeat
Day One Biopharmaceuticals Reports 2024 Financial Results - TipRanks
Day One Biopharmaceuticals, Inc. SEC 10-K Report - TradingView
Earnings Flash (DAWN) Day One Biopharmaceuticals Posts Q4 Revenue $131.2M, vs. FactSet Est of $27.8M - Marketscreener.com
Finanzdaten der Day One Biopharmaceuticals Inc-Aktie (DAWN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Day One Biopharmaceuticals Inc-Aktie (DAWN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dubow Adam | GENERAL COUNSEL |
Feb 18 '25 |
Sale |
11.96 |
4,646 |
55,580 |
39,602 |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
Feb 18 '25 |
Sale |
11.96 |
12,048 |
144,130 |
128,015 |
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):